^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Vonjo (pacritinib)

    i
    Company:
    SOBI
    Drug class:
    JAK2 inhibitor, FLT3 inhibitor, CSF-1R inhibitor, ACVR1 inhibitor, IRAK-1 inhibitor
    Related drugs:
    Apply
    Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS) (NCT06052618)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    02/27/2025
    Primary completion :
    01/01/2033
    Completion :
    01/01/2034
    CRP
    |
    Vonjo (pacritinib)
    A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression (NCT02891603)
    Phase 1/2
    H. Lee Moffitt Cancer Center and Research Insti...
    Completed
    Last update posted :
    03/25/2024
    Initiation :
    06/08/2017
    Primary completion :
    01/28/2022
    Completion :
    04/18/2022
    IL6 • HLA-DRB1 • CD4 • HLA-B • HLA-C
    |
    sirolimus • Vonjo (pacritinib)
    A Single Arm, Phase Ib/II Trial of Single Agent Pacritinib in Patients With 1q21.3 Amplified Solid Tumors Enriching for Interleukin-1 Receptor-associated Kinase 1 Pathway Activation (PAIR) (NCT04520269)
    Phase 1/2
    National University Hospital, Singapore
    Recruiting
    Last update posted :
    08/20/2020
    Initiation :
    07/13/2020
    Primary completion :
    07/01/2023
    Completion :
    07/01/2023
    S100A8
    |
    Vonjo (pacritinib)
    Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations (NCT02323607)
    Phase 1
    Bhavana Bhatnagar
    Completed
    Last update posted :
    01/25/2019
    Initiation :
    01/12/2016
    Primary completion :
    07/12/2018
    Completion :
    07/12/2018
    FLT3
    |
    FLT3 mutation
    |
    cytarabine • decitabine • daunorubicin • Vonjo (pacritinib)